Search

Your search keyword '"Gennigens C"' showing total 12 results
Start Over Author "Gennigens C" Journal annals of oncology
12 results on '"Gennigens C"'

1. Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin–paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial

Author

Powell, M.A., Bjørge, L., Willmott, L., Novák, Z., Black, D., Gilbert, L., Sharma, S., Valabrega, G., Landrum, L.M., Gropp-Meier, M., Stuckey, A., Boere, I., Gold, M.A., Segev, Y., Gill, S.E., Gennigens, C., Sebastianelli, A., Shahin, M.S., Pothuri, B., Monk, B.J., Buscema, J., Coleman, R.L., Slomovitz, B.M., Ring, K.L., Herzog, T.J., Balas, M.M., Grimshaw, M., Stevens, S., Lai, D.W., McCourt, C., and Mirza, M.R.

Published
2024
Full Text
View/download PDF

2. Molecular profiling and precision medicine in rare gastrointestinal cancers within EURACAN in the SPECTA Arcagen study (EORTC-1843): too few patients with matched treatment in Europe

Author

Lamarca, A., primary, Morfouace, M., additional, Tejpar, S., additional, Oliveira, J., additional, Capela, A., additional, Penel, N., additional, Gennigens, C., additional, Brasiuniene, B., additional, Peron, J., additional, Stevovic, A., additional, Blay, J.-Y., additional, and Klümpen, H.-J., additional

Published
2022
Full Text
View/download PDF

3. 723MO Tisotumab vedotin (TV) + carboplatin (Carbo) in first-line (1L) or + pembrolizumab (Pembro) in previously treated (2L/3L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT-Cx8/GOG-3024/innovaTV 205 study

Author

Vergote, I.B., primary, Monk, B.J., additional, O’Cearbhaill, R.E., additional, Westermann, A.M., additional, Banerjee, S., additional, Collins, D.C., additional, Mirza, M.R., additional, O'Malley, D., additional, Gennigens, C., additional, Pignata, S., additional, Melichar, B., additional, Sadozye, A., additional, Forget, F., additional, Tewari, K.S., additional, Gort, E., additional, Soumaoro, I., additional, Mondrup Andreassen, C., additional, Nicacio, L.V., additional, Van Nieuwenhuysen, E., additional, and Lorusso, D., additional

Published
2021
Full Text
View/download PDF

6. 1720P How do oncological patients perceive the COVID-19 pandemic? Experience from CHU Liège in Belgium

Author

Onesti, C.E., primary, Schroeder, H., additional, Rorive, A., additional, Sautois, B., additional, Lecocq, M., additional, Goffin, M., additional, Gonne, E., additional, Collinge, A., additional, Nicolaers, L., additional, Wera, O., additional, Catot, A., additional, Loly, C., additional, Paulus, A., additional, Sibille, A., additional, Lousberg, L.E., additional, Troisfontaine, F., additional, Collignon, J., additional, Gennigens, C., additional, Freres, P., additional, and Jerusalem, G., additional

Published
2020
Full Text
View/download PDF

7. LBA32 Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer: Results from the phase II innovaTV 204/GOG-3023/ENGOT-cx6 study

Author

Coleman, R.L., primary, Lorusso, D., additional, Gennigens, C., additional, González-Martín, A., additional, Randall, L., additional, Cibula, D., additional, Lund, B., additional, Woelber, L., additional, Pignata, S., additional, Forget, F., additional, Redondo, A., additional, Rangwala, R., additional, Vindeløv, S.D., additional, Chen, M., additional, Harris, J.R., additional, Nicacio, L., additional, Teng, M.S.L., additional, Smith, M., additional, Monk, B.J., additional, and Vergote, I.B., additional

Published
2020
Full Text
View/download PDF

8. 1712P Risk of SARS-CoV-2 infection and outcome after infection: Experience from the day-care unit at CHU Liège in Belgium

Author

Lecocq, M., primary, Onesti, C.E., additional, Schroeder, H., additional, Rorive, A., additional, Goffin, M., additional, Gonne, E., additional, Sautois, B., additional, Catot, A., additional, Wera, O., additional, Nicolaers, L., additional, Collinge, A., additional, Collignon, J., additional, Freres, P., additional, Polus, M., additional, Duysinx, B., additional, Vaillant, F., additional, Gennigens, C., additional, Marchal, N., additional, Poncin, A., additional, and Jerusalem, G., additional

Published
2020
Full Text
View/download PDF

9. A phase IIa study of tisotumab vedotin in patients with previously treated recurrent or metastatic cervical cancer: Updated analysis of full cervical expansion cohort

Author

Concin, N., primary, Vergote, I.B., additional, Lassen, U.N., additional, Drew, Y., additional, Machiels, J.-P., additional, Arkenau, H.-T., additional, Forster, M.D., additional, Jones, R., additional, Johnson, M.L., additional, Slomovitz, B.M., additional, Spicer, J., additional, Cornez, N., additional, Gennigens, C., additional, Coleman, R.L., additional, Windfeld, K., additional, Ghatta, S., additional, Rangwala, R.A., additional, and Hong, D.S., additional

Published
2018
Full Text
View/download PDF

10. A phase IIa study of tisotumab vedotin (HuMax®-TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer

Author

Vergote, I., primary, Dean, E., additional, Lassen, U., additional, de Bono, J., additional, Drew, Y., additional, Machiels, J-P., additional, Nielsen, D., additional, Arkenau, H-T., additional, Forster, M., additional, Jones, R., additional, Slomovitz, B., additional, Spicer, J., additional, Johnson, M., additional, Cornez, N., additional, Gennigens, C., additional, Fulton, B., additional, Lisby, S., additional, Basse, L., additional, Coleman, R., additional, and Hong, D.S., additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results